TheStreet.com's Feuerstein: Now that AbbVie deal is dead, Shire could spend the $1.6B breakup fee on various small biotechs, including Biomarin "If BioMarin is too much to chew, Shire could seek smaller targets to grow its orphan drug business. Let's throw out some names, including the usual suspects often mentioned as takeover bait: NPS Pharmaceuticals (NPSP) Synageva Pharma (GEVA) , Hyperion Therapeutics (HPTX) or Ultragenyx Pharma (RARE)."
"Shire is probably too risk-averse for something like this, but buying Duchenne muscular dystrophy drug makers Sarepta Therapeutics (SRPT) or Prosensa (RNA) in front of next year's expected FDA advisory panel and approval decisions would be an epic roll of the dice."